Comparison of efficacy in removal of Advanced glycation end products (AGEs) between Super high-flux Hemodialysis and Postdilution online Hemodiafiltration: A single-center, prospective, open-label, crossover randomized controlled trial
Phase 4
- Conditions
- End stage kidney disease on chronic hemodialysis, no residual kidney functionsuper high-flux hemodialysis, advanced glycation end products, online hemodiafiltration, skin autofluorescence
- Registration Number
- TCTR20230317002
- Lead Sponsor
- Mahidol university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- nknown
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
1.Age 18-80 years
2.Chronic HD
3.Adequate small molecule uremic toxins removal
4.Blood flow rate > 300 mL/min
5.RKF < 100 ml/day
6.Hemodynamically stable for > 2 weeks
Exclusion Criteria
contraindicated to anticoagulants, active malignancy, advanced liver cirrhosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Advanced glycation end products reduction 24 week skin autofluorescence
- Secondary Outcome Measures
Name Time Method serum beta2 microglobulim 1,8,16,24 week nephelometry